Edgewise Therapeutics to Host Webcast Event to Discuss Top-Line Data from Phase 1 trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy (HCM) on Thursday, September 19 at 8:30 am Eastern Time

Rhea-AI Summary

Edgewise Therapeutics (Nasdaq: EWTX) has announced a live webcast scheduled for September 19, 2024, at 8:30 am ET to discuss top-line data of their drug EDG-7500. The presentation will cover results from two trials:

1. The Phase 1 trial in healthy subjects
2. The single-dose arm of the Phase 2 CIRRUS-HCM trial in patients with obstructive Hypertrophic Cardiomyopathy (HCM)

Dr. Anjali T. Owens, Medical Director at the Center for Inherited Cardiac Disease and Associate Professor of Medicine at the University of Pennsylvania, will join the management team to share her perspective on EDG-7500 and HCM. Interested parties can register for the webcast and access the accompanying slide presentation through the Edgewise events page.

Positive

• Edgewise Therapeutics is progressing with clinical trials for EDG-7500, potentially addressing obstructive Hypertrophic Cardiomyopathy (HCM)
• The company has completed both Phase 1 and single-dose arm of Phase 2 trials, indicating advancement in drug development
• Involvement of a respected medical expert, Dr. Anjali T. Owens, in the webcast may lend credibility to the trial results

Negative

• Only top-line data will be presented, which may not provide comprehensive insights into the drug's efficacy and safety
• The Phase 2 trial results are to the single-dose arm, potentially lacking long-term efficacy and safety data

BOULDER, Colo.--(BUSINESS WIRE)-- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that members of the management team will hold a live webcast to discuss top-line data of EDG-7500 from the Phase 1 trial in healthy subjects and the single-dose arm of the Phase 2 CIRRUS-HCM trial in patients with obstructive HCM on Thursday, September 19, 2024, at 8:30 am ET. The team will be joined by CIRRUS-HCM investigator, Anjali T. Owens, M.D., Medical Director, Center for Inherited Cardiac Disease, Associate Professor of Medicine, University of Pennsylvania, who will share her perspective of EDG-7500 and HCM. An accompanying slide presentation will also be available. To register for the live webcast and replay, please visit the Edgewise events page.

About EDG-7500

EDG-7500 is a novel oral, selective, cardiac sarcomere modulator, specifically designed to slow early contraction velocity and address impaired cardiac relaxation associated with hypertrophic cardiomyopathy (HCM) and other diseases of diastolic dysfunction. To learn more about CIRRUS-HCM, visit clinicaltrials.gov, NCT06347159 (Phase 2).

About Edgewise Therapeutics

Edgewise Therapeutics is a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The Company’s deep expertise in muscle physiology is driving a new generation of novel therapeutics. Sevasemten is an orally administered skeletal myosin inhibitor in late-stage clinical trials in Becker and Duchenne muscular dystrophies. EDG-7500 is a novel cardiac sarcomere modulator for the treatment of hypertrophic cardiomyopathy and other diseases of diastolic dysfunction, currently in Phase 2 clinical development. The entire team at Edgewise is dedicated to our mission: changing the lives of patients and families affected by serious muscle diseases. To learn more, go to: www.edgewisetx.com or follow us on LinkedIn, X, Facebook and Instagram.

This press release contains hyperlinks to information that is not deemed to be incorporated by reference into this press release.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240917581066/en/

Edgewise Contacts

Investors:

Michael Carruthers, Chief Financial Officer

ir@edgewisetx.com

Media:

Maureen Franco, VP Corporate Communications

media@edgewisetx.com

Source: Edgewise Therapeutics

FAQ

What is the purpose of Edgewise Therapeutics' webcast on September 19, 2024?

The webcast is to discuss top-line data of EDG-7500 from the Phase 1 trial in healthy subjects and the single-dose arm of the Phase 2 CIRRUS-HCM trial in patients with obstructive Hypertrophic Cardiomyopathy (HCM).

What clinical trials will Edgewise Therapeutics (EWTX) be presenting results from?

Edgewise Therapeutics will present results from the Phase 1 trial in healthy subjects and the single-dose arm of the Phase 2 CIRRUS-HCM trial in patients with obstructive HCM for their drug EDG-7500.

Who is the guest speaker joining Edgewise Therapeutics' management team for the webcast?

Dr. Anjali T. Owens, Medical Director at the Center for Inherited Cardiac Disease and Associate Professor of Medicine at the University of Pennsylvania, will join the management team to share her perspective on EDG-7500 and HCM.

When and where can investors access Edgewise Therapeutics' (EWTX) webcast on September 19, 2024?

Investors can register for the live webcast scheduled for September 19, 2024, at 8:30 am ET through the Edgewise events page. An accompanying slide presentation will also be available.